Acrivastine

CLINICAL USE

Antihistamine:

Symptomatic relief of allergy such as

hayfever, urticaria

DOSE IN NORMAL RENAL FUNCTION

8 mg 3 times a day

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
348.4

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
50

%Excreted unchanged in urine &nbsp &nbsp :
60

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :
0.6–0.7

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :
1.5/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : 8 mg twice a day

10 to 20 &nbsp &nbsp : 8 mg 1–2 times a day

<10 &nbsp &nbsp &nbsp &nbsp &nbsp :
8 mg 1–2 times a day

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
Unknown dialysability. Dose as in
GFR <10 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
Unknown dialysability. Dose as in
GFR <10 mL/min

HDF/high flux &nbsp :
Unknown dialysability. Dose as in
GFR <10 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:
Unknown dialysability. Dose as in
GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antidepressants: MAOIs and tricyclics

increase the antimuscarinic and sedative
effects

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Manufacturers do not recommend use in

patients with significant renal impairment

Tags: post-by-auto-php